---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-005458"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:49:59.013145+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Corvus prioritizes CPI-818; pauses mupadolimab Phase 2; Q2 net loss $8.4M

## Summary
- Cash, cash equivalents and marketable securities $56.7M as of June 30, 2022, down from $69.5M at Dec 31, 2021.
- Net loss $8.4M for Q2 2022 vs $11.8M for Q2 2021; R&D expenses fell to $4.9M from $9.1M.
- CPI-818 200 mg cohort: 1 CR lasting 25 months, 1 nodal CR 16 months, 1 PR ongoing; no DLTs up to 600 mg.
- Pausing start of randomized Phase 2 trial of mupadolimab in front-line NSCLC to focus on CPI-818 and conserve capital.
- Expects cash runway into early 2024; full year 2022 net cash use $27-29M.

## SEC filing metadata
- accession: 0001171843-22-005458
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184322005458/0001171843-22-005458-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184322005458/f8k_080822.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-005458
- JSON: https://secwatch.observer/filing/0001171843-22-005458.json
- Plain text: https://secwatch.observer/filing/0001171843-22-005458.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.